Peginterferon-α-2b
1
Reactions 1219 - 13 Sep 2008 S Peginterferon-α-2b Hepatic sarcoidosis: case report A 44-year-old man developed hepatic sarcoidosis after receiving peginterferon-α-2b for chronic hepatitis C. The man received weight-based peginterferon-α-2b [dosage not stated] and ribavirin after laboratory tests revealed elevated liver enzymes, and a liver biopsy showed mild portal inflammation and active hepatitis C. By week 12 he had an undetectable viral load, but by week 14 his ALT level, which had remained elevated, had risen to 660 IU/L. After a liver biopsy showed granulomatous inflammation in the portal tracts and a serum angiotensin converting enzyme (ACE) level of 130 U/L, his treatment was stopped. The man’s ALT level decreased over the following 2 months. Although a further liver biopsy revealed no evidence of hepatitis C there was severe granulomatous inflammation in the portal tracts. Over the next few months, his ACE level and ALT level fell to near normal and normal levels respectively, and since then he has been asymptomatic. Author comment: "Ribavirin also inhibits [T-helper cell]2 production but preserves [T-helper cell]1 responses and thus enhances the effects of interferon alfa in the development of granulomatous inflammation." Adla M, et al. Hepatic sarcoidosis associated with pegylated interferon alfa therapy for chronic hepatitis C: case report and review of the literature. Digestive Diseases and Sciences 53: 2810-2812, No. 10, Oct 2008 - USA 801117916 1 Reactions 13 Sep 2008 No. 1219 0114-9954/10/1219-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
-
Upload
hoangxuyen -
Category
Documents
-
view
215 -
download
0
Transcript of Peginterferon-α-2b
Reactions 1219 - 13 Sep 2008
SPeginterferon-α-2b
Hepatic sarcoidosis: case reportA 44-year-old man developed hepatic sarcoidosis after
receiving peginterferon-α-2b for chronic hepatitis C.The man received weight-based peginterferon-α-2b [dosage
not stated] and ribavirin after laboratory tests revealedelevated liver enzymes, and a liver biopsy showed mild portalinflammation and active hepatitis C. By week 12 he had anundetectable viral load, but by week 14 his ALT level, whichhad remained elevated, had risen to 660 IU/L. After a liverbiopsy showed granulomatous inflammation in the portaltracts and a serum angiotensin converting enzyme (ACE) levelof 130 U/L, his treatment was stopped.
The man’s ALT level decreased over the following 2 months.Although a further liver biopsy revealed no evidence ofhepatitis C there was severe granulomatous inflammation inthe portal tracts. Over the next few months, his ACE level andALT level fell to near normal and normal levels respectively,and since then he has been asymptomatic.
Author comment: "Ribavirin also inhibits [T-helper cell]2production but preserves [T-helper cell]1 responses and thusenhances the effects of interferon alfa in the development ofgranulomatous inflammation."Adla M, et al. Hepatic sarcoidosis associated with pegylated interferon alfa therapyfor chronic hepatitis C: case report and review of the literature. Digestive Diseasesand Sciences 53: 2810-2812, No. 10, Oct 2008 - USA 801117916
1
Reactions 13 Sep 2008 No. 12190114-9954/10/1219-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
